Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 9/20 | 0.51 |
| ▸ | CDK9 | P50750 | 9/20 | 0.51 |
| ▸ | KIT | P10721 | 2/20 | 0.44 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.40 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.40 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5661225 | 0.89 | CDK9 (0.58) | CCNT1CDK9TBK1 | |
| SCHEMBL5008360 | 0.88 | CCNT1 (0.42) | CCNT1CDK9 | |
| SCHEMBL5008348 | 0.86 | CCNT1 (0.48) | CCNT1CDK9KITTBK1NAMPT | |
| SCHEMBL5004983 | 0.86 | CDK9 (0.51) | CCNT1CDK9KITTBK1NAMPT | |
| SCHEMBL5005666 | 0.85 | CCNT1 (0.49) | CCNT1CDK9KITTBK1NAMPT | |
| SCHEMBL5004893 | 0.85 | CCNT1 (0.49) | CCNT1CDK9KITTBK1NAMPT | |
| SCHEMBL13994061 | 0.85 | CCNT1 (0.55) | CCNT1CDK9KITTBK1NAMPT | |
| SCHEMBL5008380 | 0.85 | CCNT1 (0.53) | CCNT1CDK9KITTBK1NAMPT | |
| SCHEMBL5010118 | 0.83 | CCNT1 (0.51) | CCNT1CDK9KITTBK1NAMPT | |
| SCHEMBL13994065 | 0.83 | CCNT1 (0.51) | CCNT1CDK9KITTBK1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060211678-A1 | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds | OSI PHARMACEUTICALS, INC. | 2006-09-21 | — | — | US | claimed |
| US-7465726-B2 | Substituted pyrrolo[2.3-B]pyridines | OSI PHARMACEUTICALS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465726-B2 | Substituted pyrrolo[2.3-B]pyridines | OSI PHARMACEUTICALS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-20060211678-A1 | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds | OSI PHARMACEUTICALS, INC. | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211678-A1 | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds | BMX, ERBB2, FRK | CCNT1 1580/4885CDK9 428/4885KIT 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.